Cart
sales@molnova.com
FR054 (b)
CAS No. 10378-06-0
FR054 (b)( (6R)-FR054 )
Catalog No. M23246 CAS No. 10378-06-0
FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 37 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFR054 (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionFR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.
-
DescriptionFR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.
-
In Vitro——
-
In Vivo——
-
Synonyms(6R)-FR054
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|PGM3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number10378-06-0
-
Formula Weight329.31
-
Molecular FormulaC14H19NO8
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (303.67 mM; Need ultrasonic)
-
SMILESCC1=N[C@@]([C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O2)([H])[C@@]2([H])O1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Francesca Ricciardiello, et al. Inhibition of the Hexosamine Biosynthetic Pathway by Targeting PGM3 Causes Breast Cancer Growth Arrest and Apoptosis. Cell Death Dis. 2018 Mar 7;9(3):377.
molnova catalog
related products
-
Glyphosate
Glyphosate is an herbicide. It also is a possible carcinogen to humans.
-
SMIP004
SMIP004 is an SKP2 E3 ligase inhibitor. SMIP004 is a cancer cell-selective apoptosis inducer of human prostate cancer cells.
-
CWI1-2 HCL
CWI1-2 HCL is an effective IGF2BP2 inhibitor, which can induce apoptosis and differentiation by binding IGF2BP2 and inhibiting its interaction with M6A-modified target transcription, and has therapeutic effects on leukemia.
